Table 1 Advances in CAR-T cell therapy for hematologic malignancies from ESMO2024
Agent | Drug type | Study type | Disease | Accrual | Median follow-up duration | Efficacy | Major AEs | References |
|---|---|---|---|---|---|---|---|---|
ssCART-19 | Autologous IL-6-knockdown CD19 CAR-T | Phase I trial (NCT04825496) | R/R B-cell ALL | 17 (58.8% having over 50% blasts) | 19.6 m | ORR 87.5% (CR 62.5%, CRi 25.0%) within 3 m; 6-m DOR at 100% for DL1, 80% for DL2, 0% for DL3; median OS not reached | No grade ≥ 4 CRS, ICANS or related deaths | [3] |
NT-I7 | Long-acting IL-7 following CD19 CAR-T | Phase Ib trial (NCT05075603) | Advanced DLBCL | 11 (mean age 67, 81.8% III-IV stage) | N/A | ORR 81.1% (CR 63.6%); median OS 363 d; median PFS 92 d; dosed at day 21 after CAR-T infusion enhanced expansion, persistence and stemness | No CRS or ICANS | [4] |
Tisagenlecleucel | Autologous CD19 CAR-T | Real-world study | R/R FL | 129 (66.7% male, median age 63.7, median 3 prior treatment lines, 78.0% refractory, 75.0% relapsed in 6 m) | 9.8 m | ORR 98.2% (best CR 85.8%); 1.8% progression as best response; 12-m PFS 62.6%, 12-m OS 84.9%, both medians not reached | < 1% grade 3–4 CRS and/or ICANS; no adverse drug reactions led to death | [5] |
Idecabtagene vicleucel/ ciltacabtagene autoleucel vs. teclistamab | Autologous BCMA CAR-T vs. bispecifics | Real-world study | R/R MM | 391 (277 idecabtagene vicleucel, 114 ciltacabtagene autoleucel) vs. 458 (mean age 66, 54% male) | N/A | Better OS in CAR-T; older (age ≥ 70) and transplant-ineligible patients benefited more from CAR-T | More CRS in CAR-T but similar ICANS | [6] |